Effective Viscosupplement Performance
for Improved Outcomes4*

  • A three-injection series of GELSYN-3 (0.8% highly purified, hyaluronic acid of biofermentative origin) or Synvisc® (0.8% hylan G-F20)
  • Patients (n=380) were observed for a period of 26 weeks
  • Primary Outcome Measure: WOMAC pain score at 26 weeks

Clinical Outcomes

Primary-Outcome-01

Primary-Outcome-02-01

GELSYN-3 performs as well as Synvisc in terms of effectiveness and safety, providing patients with long-lasting, clinically relevant pain relief.

*Sinovial® is branded as GELSYN-3 for the US Market.